Position in DSGN
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$1,271,650
+$619,590 QoQ
Shares Held
119,516
+71.9% QoQ
Ownership
0.191%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in DSGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Lynx1 Capital Management LP holds $632,594,991 across 22 Biotechnology names. DSGN ranks #16 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | STOK |
Stoke Therapeutics, Inc.
|
4,763,673 | $155,105,192 | |
| 2 | GHRS |
GH Research PLC
|
10,763,288 | $151,331,829 | |
| 3 | CGEM |
Cullinan Therapeutics, Inc.
|
8,963,500 | $127,371,335 | |
| 4 | AGIO |
Agios Pharmaceuticals, Inc.
|
2,611,568 | $88,349,345 | |
| 5 | DNLI |
Denali Therapeutics Inc.
|
1,880,303 | $36,101,817 | |
| 6 | CCCC |
C4 Therapeutics, Inc.
|
6,998,902 | $18,407,112 | |
| 7 | KRRO |
Korro Bio, Inc.
|
1,538,296 | $17,413,510 | |
| 8 | TCRX |
TScan Therapeutics, Inc.
|
8,019,148 | $8,099,339 |
All Filings in DSGN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,271,650 | 119,516 | Shares | Other | 2026-05-04 | |
| 2025-12-31 | $652,060 | 69,516 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $496,633 | 65,954 | Shares | Other | 2025-11-13 | |
| 2025-06-30 | $222,264 | 65,954 | Shares | Other | 2025-08-14 | |
| 2025-03-31 | $254,582 | 65,954 | Shares | Other | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||